These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19803366)

  • 1. [The role of changes in matrix metalloproteases and chitotriosidase in the mechanism of protective effect of atorvastatin in experimental murine lipemia].
    Korolenko TA; Cherkanova MS; Savchenko NG; Klishevich MS
    Eksp Klin Farmakol; 2009; 72(4):25-7. PubMed ID: 19803366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of atorvastatin on activities of matrix metalloproteinases and chitotriosidase in male and female mice with experimental hyperlipidemia.
    Korolenko TA; Cherkanova MS; Korolenko EC
    Bull Exp Biol Med; 2009 Sep; 148(3):369-73. PubMed ID: 20396691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of atorvastatin on fractional and subfractional composition of serum lipoproteins and MMP activity in mice with Triton WR 1339-induced lipaemia.
    Korolenko TA; Cherkanova MS; Tuzikov FV; Johnston TP; Tuzikova NA; Loginova VM; Kaledin VI
    J Pharm Pharmacol; 2011 Jun; 63(6):833-9. PubMed ID: 21585382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.
    Korolenko TA; Tuzikov FV; Cherkanova MS; Johnston TP; Tuzikova NA; Loginova VM; Filjushina EE; Kaledin VI
    Can J Physiol Pharmacol; 2012 Feb; 90(2):141-53. PubMed ID: 22320860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractional composition of blood serum lipoproteins in mice and rats with Triton WR 1339-induced lipemia.
    Korolenko TA; Tuzikov FV; Vasil'eva ED; Cherkanova MS; Tuzikova NA
    Bull Exp Biol Med; 2010 Oct; 149(5):567-70. PubMed ID: 21165388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypolipidemic Effect of Mannan in Mice with Acute Lipemia Induced by Poloxamer 407.
    Goncharova NV; Khrapova MV; Pupyshev AB; Korolenko ET; Nešéáková Z; Korolenko TA
    Bull Exp Biol Med; 2016 Nov; 162(1):18-22. PubMed ID: 27878733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin and portal pressure.
    Zamora-Valdés D; Uribe M; Méndez-Sánchez N
    Hepatology; 2007 Oct; 46(4):1309-10; author reply 1310. PubMed ID: 17894304
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of therapy with atorvastatin on parameters of postprandial lipemia and factors of inflammation in patients with ischemic heart disease].
    Samoĭlenko EIu; Naumov VG; Tvorogova MG; Ezhov MV; Sergienko IV; Kukharchuk VV
    Kardiologiia; 2007; 47(2):4-8. PubMed ID: 17495815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
    Kosmidou MS; Hatzitolios AI; Adamidou A; Giannopoulos S; Raikos N; Parharidis G; Milionis HJ
    Am J Hypertens; 2008 Mar; 21(3):303-9. PubMed ID: 18202666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
    Szapáry L; Horváth B; Márton Z; Fehér G; Tóth K; Komoly S
    Orv Hetil; 2008 Jun; 149(24):1117-23. PubMed ID: 18539578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets.
    Kappelle PJ; Dallinga-Thie GM; Dullaart RP;
    Biochim Biophys Acta; 2010 Jan; 1801(1):89-94. PubMed ID: 19800983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties.
    Momi S; Impagnatiello F; Guzzetta M; Caracchini R; Guglielmini G; Olivieri R; Monopoli A; Gresele P
    Eur J Pharmacol; 2007 Sep; 570(1-3):115-24. PubMed ID: 17632098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of changes in serum chitotriosidase activity in mice under conditions of hyperlipidemia and lipid-lowering effect of carboxymethylated (1-3)-β-D-glycan.
    Pisareva EE; Goncharova IA; Tuzikov FV; Goncharova NV; Makhova E; Korolenko TA
    Bull Exp Biol Med; 2014 Sep; 157(5):555-9. PubMed ID: 25257411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
    Lea AP; McTavish D
    Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
    Tziakas DN; Chalikias GK; Parissis JT; Hatzinikolaou EI; Papadopoulos ED; Tripsiannis GA; Papadopoulou EG; Tentes IK; Karas SM; Chatseras DI
    Int J Cardiol; 2004 Apr; 94(2-3):269-77. PubMed ID: 15093992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate.
    Canudas J; Cenarro A; Civeira F; Garcí-Otín AL; Arístegui R; Díaz C; Masramon X; Sol JM; Hernández G; Pocoví M
    Metabolism; 2001 Apr; 50(4):447-50. PubMed ID: 11288040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of lipoprotein lipase gene expression in 3T3-L1 preadipocytes by atorvastatin, a cholesterol- and triglyceride-lowering drug.
    Bey L; Maigret P; Laouenan H; Hamilton MT
    Pharmacology; 2002 Sep; 66(1):51-6. PubMed ID: 12169766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages.
    Chi L; Peng L; Hu X; Pan N; Zhang Y
    Int J Mol Med; 2014 Jul; 34(1):283-90. PubMed ID: 24756769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of plasma level of atorvastatin and its effect on lipid profile.
    Valera HR; Ganguly B
    Indian J Physiol Pharmacol; 2009; 53(1):73-82. PubMed ID: 19810580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.